Skip to main content
CDNA
NASDAQ Industrial Applications And Services

CareDx Q2 Revenue Surges 52% to $132M, Raises 2026 Guidance

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Diagnostics & Research Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$41
Mkt Cap
$1.968B
52W Low
$11.259
52W High
$40.47
52W Position info
264% above low
Off High info
at 52W high
Rel. Volume info
1.9× avg
Market data snapshot near publication time

CDNA has more than doubled off its 52-week low of $11.259 on elevated volume (1.9× avg).

Summary

CareDx reported Q2 revenue of $132 million, up 52% year-over-year, and raised its full-year 2026 revenue and adjusted EBITDA guidance. The quarter included a $113 million gain from the sale of its lab products business and the closing of the Naveris acquisition.

Updates

  1. · Wiseek News — Stock jumped ~16% to $44.14 following the guidance raise. CareDx granted 15,822 restricted stock units to a new executive as an inducement.


Key Events · Earnings and Guidance · CDNA

  • Q2 Revenue +52% to $132M

    Total revenue reached $132 million, driven by a 61% increase in Testing Services to $100 million. Testing volume grew 17% to approximately 58,000 tests.

  • GAAP Net Income of $111M

    GAAP net income was $111 million, or $2.07 per diluted share, including a $113 million gain on the sale of the lab products business. Non-GAAP net income was $20 million, or $0.37 per diluted share.

  • Adjusted EBITDA of $25M

    Adjusted EBITDA rose to $25 million from $5 million a year ago, reflecting strong revenue growth and operating leverage.

  • Raised 2026 Guidance

    Full-year revenue guidance raised to $490–$500 million (from $447–$465 million) and adjusted EBITDA guidance raised to $66–$78 million (from $43–$57 million).


Analysis · CDNA · Industrial Applications And Services

A standout quarter for CareDx was fueled by a 61% jump in Testing Services, propelling overall revenue growth of 52%. Confidence in sustained momentum is evident as the company raised its full-year revenue and adjusted EBITDA guidance well above prior ranges. The period also featured a $113 million gain from the lab products divestiture, which closed on June 30, and the completion of the Naveris acquisition, reshaping the business around high-growth transplant diagnostics and oncology. With $374 million in cash and positive operating cash flow, the balance sheet is strong. The stock is trading near its 52-week high, reflecting the market's positive reception to the strategic transformation and improving fundamentals.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CDNA was trading at $41.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $2B. The 52-week trading range was $11.26 to $40.47. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CDNA - Latest Insights

CDNA
Oct 29, 2026, 4:04 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $78.00
Real-time Price: $77.28 info
Change: -$0.7152 (-0.92%) info
Market Cap: $4.092B info
CDNA
Oct 29, 2026, 4:02 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $80.04
Real-time Price: $77.28 info
Change: -$2.76 (-3%) info
Market Cap: $4.092B info
CDNA
Oct 29, 2026, 4:01 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $71.49
Real-time Price: $77.28 info
Change: +$5.79 (+8%) info
Market Cap: $4.092B info
CDNA
Sep 16, 2026, 4:06 PM EDT
Filing Type: 8-K/A
Importance Score:
8
Price at Filing: $53.55
Real-time Price: $77.28 info
Change: +$23.73 (+44%) info
Market Cap: $4.092B info
CDNA
Aug 03, 2026, 7:33 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $44.99
Real-time Price: $77.28 info
Change: +$32.29 (+72%) info
Market Cap: $4.092B info